Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, for LecTec Corporation (Note: The input metadata lists "Axogen, Inc.", but the filing text explicitly identifies the registrant as LecTec Corporation). The company manufactures products based on advanced skin interface technologies, including therapeutic consumer products, skin care products, and conductive/medical tape products. The company changed its fiscal year end to December 31 in September 2001.
Key Financial Metrics
| Metric | Q2 2002 | Q2 2001 | 6 Months 2002 | 6 Months 2001 |
|---|---|---|---|---|
| Net Sales | $1,583,007 | $3,411,859 | $3,097,502 | $7,160,418 |
| Gross Profit | $468,039 | $893,339 | $956,391 | $1,906,762 |
| Gross Margin | 29.6% | 26.2% | 30.9% | 26.6% |
| Net Loss | $(767,603) | $3,177,171 (Income) | $(1,574,584) | $2,633,390 (Income) |
| Cash and Equivalents | $672,248 | $1,425,205 (Dec 31, 2001) | N/A | |
| Working Capital | $(27,296) | $1,106,202 (Dec 31, 2001) | N/A | |
| Current Ratio | 1.0 | 1.4 (Dec 31, 2001) | N/A |
Debt and Liquidity: The company has a $2,000,000 asset-based line of credit with no borrowings outstanding, but it is currently in default of covenants regarding minimum book net worth and maximum loss, rendering the line unavailable. A $220,000 promissory note is due in December 2003, and an $820,000 mortgage is due in December 2002.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 53.6% in Q2 2002 and 56.7% for the six months ended June 30, 2002, compared to the prior year. This was driven by an 82.5% drop in conductive/medical tape sales (following the sale of those assets in 2001) and a 33.8% drop in therapeutic consumer product sales due to a weaker economy and cough/cold season.
- Profitability Shift: While the prior year included a one-time gain of $4.56 million from asset sales, the current period reflects a net loss. Excluding the prior year's asset sale gain and restructuring charges, the operating loss in Q2 2002 was comparable to the adjusted loss in Q2 2001.
- Expense Reduction: Operating expenses decreased significantly due to aggressive cost control measures, including reductions in compensation, product promotion, and travel expenses.
- Liquidity Deterioration: Cash and cash equivalents decreased by $752,957 over the six-month period. Working capital turned negative to a deficit of $27,296.
Outlook, Risks, and Management Commentary
- Forward Outlook: Management expects to continue operating at a net loss with negative cash flow from operations for the foreseeable future. They anticipate sales and marketing, general/administrative, and R&D expenses as a percentage of net sales will decrease in the remainder of 2002.
- Capital Needs: The company is exploring options for additional capital, including factoring receivables. Management believes current cash and factoring capabilities will sustain operations through December 2002, but future funding may require equity or debt infusions.
- Delisting Risk: On July 11, 2002, the company received a warning from Nasdaq regarding potential delisting because its stock price closed below $1.00 for 30 consecutive trading days. The company has 180 days to regain compliance.
- Covenant Default: The company is in default of its bank line of credit covenants. Until cured or waived, the credit line is unavailable.
Investor Verification Checklist
- Verify the status of the Nasdaq delisting warning and the company's plan to regain compliance by January 7, 2003.
- Confirm the timeline for curing the bank covenant defaults or obtaining a waiver to access the $2,000,000 line of credit.
- Assess the sustainability of the new skin care product line (NeoSkin) and its ability to offset declines in therapeutic patch sales.
- Review the terms of the renegotiated Supply Agreement with the major customer regarding advance payments and future order volumes.
- Monitor the company's ability to secure additional capital or factor receivables to meet the December 2002 mortgage payment and ongoing operational costs.